2. Search Result
Search Result
Results for "

JNK+inhibitor

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

2

Fluorescent Dyes

2

Biochemical Assay Reagents

2

Peptides

3

Natural
Products

2

GMP Molecules

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-12041
    SP600125
    Maximum Cited Publications
    584 Publications Verification

    		 JNK Autophagy Apoptosis Ferroptosis Cancer
    SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
    SP600125
  • HY-13319
    JNK-IN-8
    55+ Cited Publications

    JNK Inhibitor XVI

    		 JNK Cancer
    JNK-IN-8 (JNK Inhibitor XVI) is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively .
    JNK-IN-8
  • HY-N0753
    Eupalinolide B

    		Apoptosis Autophagy Reactive Oxygen Species (ROS) GSK-3 β-catenin MAP3K JNK NF-κB p38 MAPK Neurological Disease Inflammation/Immunology Cancer
    Eupalinolide B is a germ sesquiterpene. Eupalinolide B can be isolated from Eupatorium lindleyanum. Eupalinolide B induces Apoptosis, elevates ROS, promotes Autophagy. regulates GSK-3β/β-catenin, targets UBE2D3 and TAK1, activates ROS-ER-JNK, inhibits NF-κB and MAPKs. Eupalinolide B has anticancer activity against pancreatic cancer and liver cancer. Eupalinolide B relieves rheumatoid arthritis, acute lung injury, periodontitis, depression .
    Eupalinolide B
  • HY-15617
    JNK-IN-7
    5+ Cited Publications

    JNK inhibitor

    		 JNK Cancer
    JNK-IN-7 is a potent JNK inhibitor with IC50 of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, respectively.
    JNK-IN-7
  • HY-107598
    JNK Inhibitor VIII
    3 Publications Verification

    TCS JNK 6o

    		 JNK Cancer
    JNK Inhibitor VIII (TCS JNK 6o) is a c-Jun N-terminal kinases (JNK-1, -2, and -3) inhibitor with Ki values of 2 nM, 4 nM, 52 nM, respectively, and has IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively .
    JNK Inhibitor VIII
  • HY-14761
    Bentamapimod
    10+ Cited Publications

    AS 602801

    		 JNK Cancer
    Bentamapimod (AS 602801) is an ATP-competitive JNK inhibitor with IC50 of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.
    Bentamapimod
  • HY-107597
    Halicin
    2 Publications Verification

    SU3327

    		 JNK Metabolic Disease Inflammation/Immunology
    Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt kinase .
    Halicin
  • HY-15881
    TCS JNK 5a
    2 Publications Verification

    JNK Inhibitor IX

    		 JNK Apoptosis Cancer
    TCS JNK 5a is a potent JNK3 inhibitor with a pIC50 of 6.7. TCS JNK 5a also inhibits JNK2 with a pIC50 of 6.5.
    TCS JNK 5a
  • HY-10366
    BI-78D3
    1 Publications Verification

    		 JNK Metabolic Disease Cancer
    BI-78D3 functions as a substrate competitive inhibitor of JNK, inhibit the JNK kinase activity (IC50=280 nM).
    BI-78D3
  • HY-10851
    JNK-9L

    		JNK Reactive Oxygen Species (ROS) Neurological Disease
    JNK-9L (Compound 9l) is a BBB-penetrable and ATP-competitive JNK inhibitor with IC50s of 0.099 and 0.148  μM for JNK1 and JNK3, respectively. JNK-9L significantly inhibits c-jun phosphorylation and Streptozotocin (HY-13753)-induced ROS generation with an IC50 of 0.8  nM. JNK-9L can be used for neurodegenerative disorders like Parkinson’s disease research .
    JNK-9L
  • HY-112402
    SP 600125, negative control

    JNK Inhibitor II, negative control

    		 Autophagy Apoptosis JNK Ferroptosis Cancer
    SP 600125, negative control (SPM1) is an alkyl derivative of pyrazoloanthrone, which can be used as a negative control for SP600125 (HY-12041) .
    SP 600125, negative control
  • HY-150053
    JNK-IN-11
    1 Publications Verification

    		 JNK Neurological Disease
    JNK-IN-11 (compound 1) is a potent JNK inhibitor with an IC50 value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease .
    JNK-IN-11
  • HY-149930
    YL5084

    		JNK Apoptosis Cancer
    YL5084, a covalent JNK inhibitor, exhibits selectivity for JNK2 and JNK3 over JNK1 with IC50s of 70 nM, 84 nM and 2173 nM, respectively. YL5084 exhibits JNK2-independent antiproliferative effects and induces apoptosis in a JNK2-independent manner .
    YL5084
  • HY-13319G
    JNK-IN-8

    JNK Inhibitor XVI

    		 JNK Cancer
    JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent JNK inhibitor with IC50s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively .
    JNK-IN-8
  • HY-P2243
    D-JBD19

    		JNK Neurological Disease
    D-JBD19 is an impermeable peptide that serves as an inactive control for the JNK inhibitor D-JNKI1 (HY-P0069). D-JNKI1 has neuroprotective effects .
    D-JBD19
  • HY-77009
    JNK-IN-13

    		JNK Cancer
    JNK-IN-13 (compound 1) is a potent and selective JNK inhibitor with IC50s of 290 nM and 500 nM for JNK3 and JNK2, respectively .
    JNK-IN-13
  • HY-157551
    JNK-IN-16

    		JNK c-Met/HGFR Cancer
    JNK-IN-16 is a c-Met and JNK inhibitor with nanomolar potency, with IC50 values of 120 nM and 72 nM, respectively. JNK-IN-16 can be used for cancer research .
    JNK-IN-16
  • HY-P10140
    JNK-IN-15, Cell-Permeable

    		JNK Cancer
    JNK-IN-15, Cell-Permeable (JNK inhibitor III) is an inhibitor of JNK. JNK-IN-15, Cell-Permeable can used in study age-related neurodegenerative diseasev .
    JNK-IN-15, Cell-Permeable
  • HY-N7394A
    (-)-Zuonin A
    1 Publications Verification

    D-Epigalbacin

    		 JNK Cancer
    (-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective JNKs inhibitor, with IC50s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively .
    (-)-Zuonin A
  • HY-112894
    ZG-10

    		JNK SARS-CoV Inflammation/Immunology
    ZG-10 (JNK-IN-2) is a JNK inhibitor, with IC50 values of 809 nM, 1140 nM and 709 nM for JNK1, JNK2, and JNK3, respectively. ZG-10 (JNK-IN-2) is a potential anti-SARS-CoV-2 agent .
    ZG-10
  • HY-156182
    JNK-IN-14

    		JNK Apoptosis Cancer
    JNK-IN-14 is a potent and selective JNK inhibitor with IC50 values of 1.81, 12.7 and 10.5 nM for JNK1, JNK2 and JNK3, respectively. JNK-IN-14 induces early-stage apoptosis and G2/M cell cycle arrest. JNK-IN-14 can be used for cancer research
    JNK-IN-14
  • HY-175276
    JNK-IN-24

    		JNK MMP Cancer
    JNK-IN-24, a JNK inhibitor, is an anti-metastatic cancer agent. JNK-IN-24 downregulates JNK and MMP1 expression in Scrib knockdown induced cancer tissues. JNK-IN-24 promotes recovery from tumorous wing disc phenotype of Scrib RNAi. JNK-IN-24 can be used for the study in various epithelial cell-derived cancers .
    JNK-IN-24
  • HY-12041R
    SP600125 (Standard)

    		JNK Autophagy Apoptosis Ferroptosis Cancer
    SP600125 (Standard) is the analytical standard of SP600125. This product is intended for research and analytical applications. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
    SP600125 (Standard)
  • HY-155077
    JNK-IN-12

    		JNK Cancer
    JNK-IN-12 (compound P2) is a mitochondrial-targeted JNK inhibitor (IC50=66.3 nM), consisting of a mitochondrial-specific cell-penetrating peptide and a specific inhibitor of JNK, SP600125 (HY-12041). JNK-IN-12 doesn't inhibit nuclear JNK signaling, but does inhibit mitochondrial JNK phosphorylation. JNK-IN-12 helps to improve the Parkinson's disease (PD) both in vitro and in vivo .
    JNK-IN-12
  • HY-15495B
    (3S)-Tanzisertib hydrochloride

    (3S)-CC-930 hydrochloride

    		 JNK ERK p38 MAPK EGFR TNF Receptor Inflammation/Immunology
    (3S)-Tanzisertib (hydrochloride) ((3S)-CC-930 (hydrochloride)) is an orally active JNK inhibitor (IC50 values for JNK1, JNK2, and JNK3 are 61, 7, and 6 nM, respectively). (3S)-Tanzisertib (hydrochloride) selectively inhibits ERK1, p38α, and EGFR (IC50 = 0.48, 3.4, and 0.38 μM, respectively). (3S)-Tanzisertib (hydrochloride) inhibits LPS-induced TNFα production in an acute rat PK-PD model. (3S)-Tanzisertib (hydrochloride) can be used in idiopathic pulmonary fibrosis (IPF) research .
    (3S)-Tanzisertib hydrochloride
  • HY-169052
    Cyy-272

    		JNK Apoptosis Cardiovascular Disease Inflammation/Immunology
    Cyy-272 is an orally active JNK inhibitor with IC50 values of 1.25 μM for JNK1, 1.07 μM for JNK2, and 1.24 μM for JNK3. Cyy-272 exerts anti-inflammatory effects by inhibiting JNK phosphorylation, thereby alleviating acute lung injury (ALI) induced by lipopolysaccharide (LPS, HY-D1056). Additionally, Cyy-272 significantly reduces inflammation in cardiomyocytes and cardiac tissue induced by high lipid concentrations, further mitigating cardiac hypertrophy, fibrosis, and apoptosis. Cyy-272 can be used in the study of obese cardiomyopathy .
    Cyy-272
  • HY-N0699R
    Daphnoretin (Standard)

    Dephnoretin (Standard); Thymelol (Standard)

    		 Reference Standards PKC NOD-like Receptor (NLR) Apoptosis HBV Caspase Akt JNK PI3K CDK Influenza Virus Bcl-2 Family Infection Inflammation/Immunology Cancer
    Daphnoretin (Dephnoretin; Thymelol) (Standard) is the analytical standard of Daphnoretin (HY-N0699). This product is used for research and analytical applications. Daphnoretin is a protein kinase C (PKC) activator that can inhibit the expression of hepatitis B virus (HBV) surface antigen (HBsAg) and has antiviral activity. Daphnoretin exerts its anti-tumor effect by inhibiting the activation of the PI3K/AKT signaling pathway, triggering the mitochondrial apoptosis pathway. Daphnoretin alleviates chondrocyte apoptosis and inflammatory responses by inhibiting endoplasmic reticulum stress and the activation of the NLRP3 inflammasome. Daphnoretin can regulate the differentiation and maturation of dendritic cells, by down-regulating the phosphorylation level of JNK, inhibiting its immune stimulating function, thereby playing a protective role in skin transplant rejection reactions.
    Daphnoretin (Standard)
  • HY-107598R
    JNK Inhibitor VIII (Standard)

    TCS JNK 6o (Standard)

    		 Reference Standards JNK Cancer
    JNK Inhibitor VIII (Standard) is the analytical standard of JNK Inhibitor VIII (HY-107598). This product is intended for research and analytical applications. JNK Inhibitor VIII (TCS JNK 6o) is a c-Jun N-terminal Kinases (JNK-1, -2, and -3) inhibitor with Ki values of 2 nM, 4 nM, 52 nM, respectively, and has IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively .
    JNK Inhibitor VIII (Standard)
  • HY-49924
    JNK-IN-26

    		JNK Others
    JNK-IN-26 (JNK-IN-11) is a JNK inhibitor .
    JNK-IN-26
  • HY-169634
    JD118

    		JNK Cancer
    JD118 is a JNK inhibitor. JD118 inhibits JNK1 activity and the expression of cJun (1–135) .
    JD118
  • HY-169674
    JNK-IN-20

    		JNK Inflammation/Immunology Cancer
    JNK-IN-20 (compound 5) is a JNK inhibitor. JNK-IN-20 can be used in inflammation and tumor related research .
    JNK-IN-20
  • HY-10366R
    BI-78D3 (Standard)

    		Reference Standards JNK Metabolic Disease Cancer
    BI-78D3 (Standard) is the analytical standard of BI-78D3 (HY-10366). This product is intended for research and analytical applications. BI-78D3 functions as a substrate competitive inhibitor of JNK, inhibit the JNK kinase activity (IC50=280 nM).
    BI-78D3 (Standard)
  • HY-107597R
    Halicin (Standard)

    SU3327 (Standard)

    		 Reference Standards JNK Metabolic Disease Inflammation/Immunology
    Halicin (Standard) is the analytical standard of Halicin (HY-107597). This product is intended for research and analytical applications. Halicin (SU3327) is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. Halicin also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. Halicin shows less active against p38α and Akt Kinase .
    Halicin (Standard)
  • HY-12041G
    SP600125

    		JNK Autophagy Apoptosis Ferroptosis Cancer
    SP600125 (GMP) is SP600125 (HY-12041) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis .
    SP600125
  • HY-164111
    JNK-IN-17

    		JAK Neurological Disease
    JNK-IN-17 (Compound 9J) is a selective and potent JNK inhibitor with IC50 values of 0.039, 0.079 μM for JNK1 and JNK3. JNK-IN-17 can inhibit c-Jun phosphorylation with an IC50 of 0.082 μM in Streptozotocin (HY-13753)-infuced INS-1 pancreatic islet β cells. JNK-IN-17 shows inhibition rate ≤ 33% on the four main P450 subtypes (2C9, 2D6, 3A4, 1A2) in human liver microsomes, indicating a relatively low risk of drug interactions. JNK-IN-17 can be used for researches of neurological and metabolic disease, such as Parkinson's disease .
    JNK-IN-17

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: